Equities analysts expect Alimera Sciences Inc (NASDAQ:ALIM) to announce earnings per share (EPS) of ($0.37) for the current fiscal quarter, according to Zacks Investment Research. Two analysts have provided estimates for Alimera Sciences’ earnings, with the highest EPS estimate coming in at ($0.32) and the lowest estimate coming in at ($0.42). The firm is expected to issue its next earnings report on Tuesday, February 4th.

According to Zacks, analysts expect that Alimera Sciences will report full-year earnings of ($2.62) per share for the current fiscal year, with EPS estimates ranging from ($2.63) to ($2.61). For the next year, analysts expect that the business will report earnings of ($1.02) per share, with EPS estimates ranging from ($1.04) to ($0.99). Zacks Investment Research’s EPS averages are an average based on a survey of sell-side research analysts that that provide coverage for Alimera Sciences.

Alimera Sciences (NASDAQ:ALIM) last issued its quarterly earnings data on Tuesday, October 29th. The biopharmaceutical company reported ($0.60) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.60). The business had revenue of $12.85 million during the quarter, compared to the consensus estimate of $12.75 million.

ALIM has been the subject of a number of recent analyst reports. HC Wainwright reissued a “buy” rating and issued a $15.00 price objective on shares of Alimera Sciences in a report on Wednesday, December 4th. Zacks Investment Research lowered Alimera Sciences from a “buy” rating to a “hold” rating in a report on Monday. B. Riley set a $30.00 price objective on Alimera Sciences and gave the stock a “buy” rating in a report on Monday, September 30th. Finally, ValuEngine raised Alimera Sciences from a “hold” rating to a “buy” rating in a report on Tuesday, December 3rd. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. Alimera Sciences presently has an average rating of “Buy” and a consensus target price of $24.50.

ALIM stock traded up $0.39 on Friday, reaching $7.08. The company’s stock had a trading volume of 65,766 shares, compared to its average volume of 50,563. Alimera Sciences has a 52 week low of $2.96 and a 52 week high of $18.15. The firm has a fifty day moving average of $7.20 and a two-hundred day moving average of $2.46.

In other news, Director John Snisarenko purchased 10,000 shares of the firm’s stock in a transaction on Thursday, November 21st. The stock was purchased at an average cost of $4.95 per share, with a total value of $49,500.00. Following the purchase, the director now owns 10,000 shares in the company, valued at approximately $49,500. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Richard S. Eiswirth, Jr. purchased 100,000 shares of the firm’s stock in a transaction on Thursday, November 14th. The shares were purchased at an average cost of $5.21 per share, with a total value of $521,000.00. Over the last ninety days, insiders have acquired 114,000 shares of company stock valued at $595,270. 14.60% of the stock is currently owned by corporate insiders.

An institutional investor recently raised its position in Alimera Sciences stock. Renaissance Technologies LLC raised its position in shares of Alimera Sciences Inc (NASDAQ:ALIM) by 13.1% in the second quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 1,128,404 shares of the biopharmaceutical company’s stock after purchasing an additional 130,414 shares during the quarter. Renaissance Technologies LLC owned about 1.59% of Alimera Sciences worth $1,004,000 as of its most recent SEC filing.

Alimera Sciences Company Profile

Alimera Sciences, Inc, a pharmaceutical company, engages in the research, development, and commercialization of prescription ophthalmic pharmaceuticals in the United States and internationally. It focuses on diseases affecting the back of the eye or retina. The company offers ILUVIEN, an intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and could lead to severe vision loss and blindness.

Read More: Trading Ex-Dividend Strategy

Get a free copy of the Zacks research report on Alimera Sciences (ALIM)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Alimera Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alimera Sciences and related companies with MarketBeat.com's FREE daily email newsletter.